Amneal Pharmaceuticals has reported a 17% jump in its generics revenue to $342m in the third quarter of 2020, compared to the prior-year period. Commenting on the growth of the generics division, Chirag Patel, co-CEO, president and director of Amneal, said “the double-digit net revenue growth reflects the successful launch of eight of the 15 complex new products we target launching by August 2021.”
Chintu Patel, co-CEO and director of Amneal commented that “our generics business continues to improve with strong sales and increasing...
